Американское общество гирудотерапии

Greater Trochanteric Pain Syndrome (Investigational)

Investigational adjunct for chronic greater trochanteric pain syndrome (gluteal tendinopathy); load management and hip-abductor strengthening remain primary.

Tier C — InvestigationalИсследовательское применениеLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Краткая информация для пациента

Есть ли FDA-допуск для этого показания?
Not FDA-cleared for greater trochanteric pain syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
Какие доказательства существуют?
Tier C (investigational). There are no published controlled trials. Greater trochanteric pain syndrome (lateral hip pain) most often reflects gluteus medius/minimus tendinopathy or trochanteric bursitis. Evidence-based care: activity modification, load management, hip-abductor strengthening (the strongest RCT support), gait retraining, weight management if applicable, NSAIDs for short-term symptoms, corticosteroid injection (effective short-term but limited long-term), and shock-wave therapy or PRP for refractory cases. Surgery (bursectomy, gluteus tendon repair) is reserved for refractory tendinopathy with tendon tears.
Основные риски
  • Bleeding from each bite site for 6 to 24 hours after detachment
  • Bruising over the lateral hip for 5 to 10 days
  • Local skin or, rarely, Aeromonas hydrophila infection
  • Allergic reaction to leech saliva (uncommon)
  • Risk of triggering a flare if leech is placed too close to an inflamed bursa or tendon
  • Septic bursitis if a contaminated bite penetrates near the trochanteric bursa
  • Delay of evidence-based hip-abductor strengthening - the highest-evidence intervention
Кому не следует это рассматривать
  • Patients with suspected gluteus medius or minimus tendon tear on imaging (may need surgical evaluation)
  • Patients with hip osteoarthritis, femoroacetabular impingement, or lumbar radiculopathy mimicking the syndrome
  • Patients with recent corticosteroid injection at the site (within 4 weeks)
  • Patients who have not completed at least 8 to 12 weeks of structured hip-abductor strengthening
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients with active dermatitis or broken skin over the lateral hip
О чём спросить врача
  • Have I had an MRI or ultrasound to rule out gluteus tendon tear?
  • Have I been worked up for hip osteoarthritis, FAI, or lumbar radiculopathy as alternatives?
  • Have I completed a structured 8 to 12 week hip-abductor strengthening program with a sports-medicine-trained physical therapist?
  • Have I tried corticosteroid injection, and what is its evidence vs. this investigational option?
  • Where exactly will leeches be placed - confirm placement is lateral to (not directly on) the most tender point?
  • What is the practitioner's plan if symptoms do not improve after 2 to 3 sessions?
  • What is the Aeromonas-prevention protocol?
Когда срочно обратиться за медицинской помощью
  • Sudden inability to bear weight, hip instability, or loss of single-leg balance (possible tendon tear)
  • Acute severe lateral hip swelling with warmth (possible septic bursitis)
  • Calf swelling, redness, or warmth (possible DVT)
  • Bleeding from a bite site lasting more than 24 hours
  • Fever, chills, or spreading redness at the bite site
  • Hives, facial or throat swelling, or breathing difficulty

Что это НЕ означает

  • This is not FDA-cleared for greater trochanteric pain syndrome.
  • No published controlled trials exist; placebo response is high in chronic overuse syndromes.
  • It does not replace hip-abductor strengthening, which has the strongest RCT support.
  • It does not address underlying gluteus tendon tear, which may need surgical evaluation.
  • Activity modification and load management remain essential and are not substituted by procedural therapy.

Clinical Profile

Category
musculoskeletal
ICD-10
M70.60, M70.70
Safety tier
medium

Evidence Summary

Greater trochanteric pain syndrome (GTPS) is most often gluteus medius and minimus insertional tendinopathy with or without trochanteric bursal involvement. Evidence-based management is education and load modification, progressive abductor strengthening (especially isometric early), with selective corticosteroid injection for short-term pain relief and PRP under investigation. The LEAP trial (Mellor et al., 2018) showed superior outcomes for exercise-plus-education versus corticosteroid injection at both 8 and 52 weeks. No controlled clinical trial of hirudotherapy for GTPS has been published; any use is investigational and mechanistic only, and the underlying gluteal tendinopathy still requires loading rehabilitation.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Wollina U (2008)0

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Hip osteoarthritis as primary diagnosis (refer to orthopedics)
  • Lumbar radiculopathy with referred lateral hip pain (workup first)
  • Recent corticosteroid injection at the site (within 4 weeks)
  • Hip prosthesis adjacent to placement site

Related Conditions

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.

Greater Trochanteric Pain Syndrome (Investigational) — Hirudotherapy Evidence | ASH